Skip to main content

Beckman Coulter to Buy Remainder of NexGen

NEW YORK (GenomeWeb News) – Beckman Coulter said yesterday it has agreed to buy the remaining 80.1 percent of NexGen Diagnostics, a spin-out of Lumigen, which it bought in late 2006 for $185 million. 
NexGen owns intellectual property that Beckman Coulter hopes to use for immunoassay and nucleic acid-based diagnostic testing.
Because NexGen’s assets are in the form of intellectual property that will require development, Beckman Coulter said it expects to take a charge of around $36 million for in-process R&D after the deal closes in the fourth quarter of 2007.
The IP is centered on a non-separation immunoassay technology that cuts out “time-consuming steps,” Beckman said, adding that it allows “rapid isolation of DNA or RNA from a patient sample without a separate step or reagent.”
Financial terms of the agreement were not released.
The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.